Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib versus investigator's choice or observation after resection in KRAS G12C-positive stage II-III non-small cell lung cancer
NL-OMON61566Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of divarasib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Roche. Primary endpoint: Disease-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61566.